keyword
MENU ▼
Read by QxMD icon Read
search

Sarcomatoid Renal Cell Carcinoma

keyword
https://www.readbyqxmd.com/read/28938681/high-mucin-5ac-expression-predicts-adverse-postoperative-recurrence-and-survival-of-patients-with-clear-cell-renal-cell-carcinoma
#1
Haijian Zhang, Yidong Liu, Huyang Xie, Weisi Liu, Qiang Fu, Dengfu Yao, Jiejie Xu, Jianxin Gu
BACKGROUND: Mucin 5AC (MUC5AC), as a member of secreted/gel-forming mucin family, was frequently found to be abnormally expressed in inflammation or malignant diseases. However, the clinic pathologic features and prognostic values of MUC5AC in clear-cell renal cell carcinoma (ccRCC) have not been reported up to now. METHODS: MUC5AC expression was analyzed by immunohistochemistry on tissue microarrays. Kaplan-Meier survival curves, Univariate and Multivariate Cox analysis and newly-established nomogram model were performed to evaluate the prognostic value...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28937382/malignant-fibrous-histiocytoma-arising-from-renal-capsule-an-extremely-rare-entity
#2
Shilpa Bairwa, Ashok Sangwaiya, Mariyam Ansari, Arpita Jindal, Sapna Singla, Ajay Yadav
Malignant fibrous histiocytoma (MFH) usually presents in the extremities or retroperitoneum. MFH arising from renal parenchyma or renal capsule is extremely rare, only few cases have been reported in literature and portend a poor prognosis. Renal MFH is differentiated from renal cell carcinoma, renal sarcoma, and sarcomatoid renal tumor only by histological and immunohistochemical studies. Since the therapeutic options for MFH are different, its early diagnosis is imperative. Herein, we report a case of a primary renal MFH in a 35-year-old male...
July 2017: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/28932952/survival-of-metastatic-renal-cell-carcinoma-patients-continues-to-improve-over-time-even-in-targeted-therapy-era
#3
Michele Marchioni, Marco Bandini, Raisa S Pompe, Zhe Tian, Tristan Martel, Anil Kapoor, Luca Cindolo, Francesco Berardinelli, Alberto Briganti, Shahrokh F Shariat, Luigi Schips, Pierre I Karakiewicz
OBJECTIVE: To examine the effect of diagnosis year, defined as contemporary (2010-2014), intermediate (2006-2009) and historical (2001-2005) on cancer-specific mortality (CSM) in patients with metastatic renal cell carcinoma (mRCC). METHODS: Within Surveillance, Epidemiology, and End Results registry (2001-2014), we identified patients with mRCC. Cumulative incidence and competing risks regression (CRR) models examined CSM, after accounting for other-cause mortality...
September 20, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28927783/surgical-resection-of-locally-recurrent-renal-cell-carcinoma-after-nephrectomy-oncological-outcome-and-predictors-of-survival
#4
Roman Herout, Johannes Graff, Angelika Borkowetz, Stefan Zastrow, Steffen Leike, Rainer Koch, Desiree-Louise Draeger, Chris Protzel, Oliver W Hakenberg, Manfred P Wirth, Michael Froehner
OBJECTIVE: To describe the course of disease of patients surgically treated for locally recurrent renal cell carcinoma (LRRCC) after nephrectomy and to identify potential predictive factors for long-term survival. PATIENTS AND METHODS: We, retrospectively, identified 54 patients who underwent surgical resection of LRRCC after open nephrectomy for localized kidney cancer. The median age at time of surgery for LRRCC was 65 years. Survival rates were determined with the Kaplan-Meier method...
September 15, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28912138/sarcomatoid-renal-cell-carcinoma-the-apple-doesn-t-fall-far-from-the-tree
#5
Paulo Bergerot, Neeraj Agarwal, Sumanta Kumar Pal, Jeremy O Jones
The most comprehensive sequencing effort of sarcomatoid renal cell carcinoma (sRCC) to date reinforces the notion that the sarcomatoid component is closely related to the epithelial component of the cancer. This work also challenges the notion that sRCC evolves from low grade RCC and identifies potential mediators of sarcomatoid differentiation.
September 14, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28892918/sarcomatoid-carcinoma-of-renal-pelvis-with-abundant-heterologous-osteosarcomatous-element-a-case-report
#6
Mona Lisa, Guddi Rani Singh, Richa Madhawi, Bipin Kumar, Zeenat Sarmadi Imam
A 47-year-old male presented with haematuria and flank pain for two weeks. Ultrasonography and renal scan revealed a poorly functioning left kidney with multiple calculi. Simple nephrectomy was performed and the specimen revealed a mass in his renal pelvis which showed both carcinomatous and sarcomatous components on microscopy. The sarcomatous component consisted of diffuse pleomorphic osteoblasts with intervening lacy osteoid, giving an osteosarcoma-like appearance. These areas of tumour were strongly positive for vimentin and osteopontin...
July 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28890070/oligometastatic-renal-cell-carcinoma-with-sarcomatoid-differentiation-demonstrating-variable-imaging-phenotypes-on-68-ga-psma-and-18-f-fdg-pet-ct-a-case-report-and-review-of-the-literature
#7
David P Nadebaum, Michael S Hofman, Catherine A Mitchell, Shankar Siva, Rodney J Hicks
No abstract text is available yet for this article.
August 23, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28882777/secondary-urethral-malignancies-following-prostate-brachytherapy
#8
Shree Agrawal, John M Lacy, Herman Bagga, Kenneth W Angermeier, Jay Ciezki, Rahul D Tendulkar, Chandana A Reddy, Hadley M Wood
OBJECTIVE: To understand urethral secondary malignancies among patients treated with brachytherapy (BRT) for primary prostate cancer. METHODS: Institutional retrospective review identified 13 patients evaluated from 2003-2014 with urethral cancer and prior history of BRT monotherapy for prostate cancer. All patients were biochemically free of their primary disease and developed histologically distinct RASM from primary tumor via pathologic confirmation. BRT characteristics, patient age, presentation, staging work-up and clinical course were evaluated...
September 4, 2017: Urology
https://www.readbyqxmd.com/read/28870517/phase-2-trial-of-capecitabine-gemcitabine-and-bevacizumab-in-sarcomatoid-renal-cell-carcinoma
#9
Abhishek Maiti, Maryam Nemati-Shafaee, Pavlos Msaouel, Lance C Pagliaro, Eric Jonasch, Nizar M Tannir, Amishi Y Shah
BACKGROUND: Patients with sarcomatoid renal-cell carcinomas (sRCC) have poor outcomes and limited treatment options. Preclinical and clinical data suggest susceptibility to cytotoxic agents and vascular endothelial growth factor-targeted therapies. We designed a phase 2 trial to evaluate the efficacy and safety of capecitabine, gemcitabine, and bevacizumab in sRCC. PATIENTS AND METHODS: Patients with metastatic or unresectable sRCC were eligible for inclusion. Patients received oral capecitabine 800 mg/m(2) twice daily on days 1 to 21 of a 28-day cycle, intravenous gemcitabine 900 mg/m(2) on days 1 and 15, and intravenous bevacizumab 10 mg/kg on days 1 and 15...
August 10, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28833389/morphologic-spectrum-of-renal-cell-carcinoma-unclassified-an-analysis-of-136-cases
#10
Carmen M Perrino, David J Grignon, Sean R Williamson, Muhammad T Idrees, John N Eble, Liang Cheng
AIMS: Renal cell carcinoma, unclassified (RCCU) is a category that includes a morphologically and biologically heterogeneous group of tumors that are unable to be diagnosed as other well-defined entities. We aim to describe the morphologic findings of tumors within this category and to determine the most frequent morphologic features leading to classification difficulty. METHODS AND RESULTS: One hundred and thirty-six cases of RCCU were examined. Patients ranged in age from 23 to 87 years...
August 18, 2017: Histopathology
https://www.readbyqxmd.com/read/28832979/programmed-cell-death-ligand-1-and-tumor-infiltrating-lymphocyte-status-in-patients-with-renal-cell-carcinoma-and-sarcomatoid-dedifferentiation
#11
Fumi Kawakami, Kanishka Sircar, Jaime Rodriguez-Canales, Bryan M Fellman, Diana L Urbauer, Pheroze Tamboli, Nizar M Tannir, Eric Jonasch, Ignacio I Wistuba, Christopher G Wood, Jose A Karam
BACKGROUND: The immune profile of sarcomatoid renal cell carcinoma (sRCC), including the programmed cell death ligand 1 (PD-L1) and programmed cell death 1 (PD-1) status, has not been well characterized. METHODS: An immunohistochemical digital analysis of PD-L1, PD-1, CD4, and CD8 was performed on nephrectomy specimens from 118 sRCC patients and 92 nonsarcomatoid clear cell renal cell carcinoma (ccRCC) patients. The clinical characteristics of the population were compared between sRCC and ccRCC...
August 22, 2017: Cancer
https://www.readbyqxmd.com/read/28803448/microvascular-and-lymphovascular-tumor-invasion-are-associated-with-poor-prognosis-and-metastatic-spread-in-renal-cell-carcinoma-a-validation-study-in-clinical-practice
#12
Jens Bedke, Johannes Heide, Silvia Ribback, Steffen Rausch, Michela de Martino, Marcus Scharpf, Andrea Haitel, Uwe Zimmermann, Maik Pechoel, Hussam Alkhayyat, Shahrokh F Shariat, Frank Dombrowski, Arnulf Stenzl, Martin Burchardt, Tobias Klatte, Nils Kroeger
OBJECTIVE: To validate microvascular (MVI) and lymphovascular (LVI) invasion as a prognostic factor in renal cell carcinoma patients (pts.) MATERIALS AND METHODS: Data of patients with RCC who underwent radical or nephron sparing surgery were prospectively collected from three academic centers. The occurrence of MVI and LVI was determined with standard staining protocols by experienced pathologists at the time of diagnosis. The association of MVI and LVI with clinicopathological data, metastatic spread and cancer-specific survival (CSS) was evaluated with Fisher's exact tests, binary logistic regression analyses and univariable and multivariable Cox proportional hazard regression models...
August 13, 2017: BJU International
https://www.readbyqxmd.com/read/28778070/the-association-between-renal-sinus-fat-area-and-the-progression-free-survival-in-chinese-non-metastatic-clear-cell-renal-cell-carcinoma-patients
#13
Haichao Huang, Shi Chen, Wei Yu, Zirong Ye, Wei Li, Jinchun Xing, Xiurong Wu
In this retrospective study, we evaluated the association between renal sinus fat area (RSFA) and survival in 268 Chinese non-metastatic clear-cell renal cell carcinoma (ccRCC) patients. Patients with high RSFA exhibited better progression-free survival than those with low RSFA in both univariable (HR: 0.240; 95% CI: 0.119-0.482; p < 0.001) and multivariable (HR: 0.432; 95% CI: 0.369-2.749; p = 0.027) analyses. A propensity-score matched (PSM) analysis using Kaplan-Meier curves confirmed our findings (log-rank test; p = 0...
July 5, 2017: Oncotarget
https://www.readbyqxmd.com/read/28749793/pax8-expression-in-solitary-fibrous-tumor-a-potential-diagnostic-pitfall
#14
David Ullman, Jennifer Gordetsky, Gene P Siegal, Carlos N Prieto-Granada, Shi Wei, Todd M Stevens
PAX8 is used as a diagnostic aid in classifying retroperitoneal (RP) spindle cell tumors. PAX8 positivity in a spindled RP tumor is typically associated with sarcomatoid renal cell carcinoma (SRCC). However, PAX8 expression in solitary fibrous tumor (SFT), a tumor not uncommon to the RP, has not been extensively studied. We investigated the expression of PAX8 in SFTs and other spindle cell RP tumors. We collected 30 SFT, 23 SRCC, 11 gastrointestinal stromal tumors, 2 synovial sarcomas, 6 dedifferentiated liposarcomas (DDLS), 4 well differentiated liposarcomas (WDLS), and select other tumors...
July 26, 2017: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/28736828/genomic-and-metabolic-characterization-of-a-chromophobe-renal-cell-carcinoma-cell-line-model-uok276
#15
Youfeng Yang, Cathy D Vocke, Christopher J Ricketts, Darmood Wei, Hesed M Padilla-Nash, Martin Lang, Carole Sourbier, J Keith Killian, Shawna L Boyle, Robert Worrell, Paul S Meltzer, Thomas Ried, Maria J Merino, Adam R Metwalli, W Marston Linehan
Chromophobe renal cell carcinoma (ChRCC) represents 5% of all RCC cases and frequently demonstrates multiple chromosomal losses and an indolent pattern of local growth, but can demonstrate aggressive features and resistance to treatment in a metastatic setting. Cell line models are an important tool for the investigation of tumor biology and therapeutic drug efficacy. Currently, there are few ChRCC-derived cell lines and none is well characterized. This study characterizes a novel ChRCC-derived cell line model, UOK276...
October 2017: Genes, Chromosomes & Cancer
https://www.readbyqxmd.com/read/28731045/renal-cell-tumors-with-clear-cell-histology-and-intact-vhl-and-chromosome-3p-a-histological-review-of-tumors-from-the-cancer-genome-atlas-database
#16
Laura Favazza, Dhananjay A Chitale, Ravi Barod, Craig G Rogers, Shanker Kalyana-Sundaram, Nallasivam Palanisamy, Nilesh S Gupta, Sean R Williamson
Clear cell renal cell carcinoma is by far the most common form of kidney cancer; however, a number of histologically similar tumors are now recognized and considered distinct entities. The Cancer Genome Atlas published data set was queried (http://cbioportal.org) for clear cell renal cell carcinoma tumors lacking VHL gene mutation and chromosome 3p loss, for which whole-slide images were reviewed. Of the 418 tumors in the published Cancer Genome Atlas clear cell renal cell carcinoma database, 387 had VHL mutation, copy number loss for chromosome 3p, or both (93%)...
July 21, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28725540/the-pathology-and-molecular-genetics-of-sarcomatoid-renal-cell-carcinoma-a-mini-review
#17
REVIEW
Shuanzeng Wei, Tahseen Al-Saleem
Sarcomatoid renal cell carcinoma is a highly aggressive tumor. It is not a distinct histologic entity as it can be found in any subtypes of renal cell carcinoma. Recent molecular and genetic evidence suggest that sarcomatoid component is transformed from a common progenitor of the associated renal cell carcinoma, and the TP53 gene plays a pivotal role in this process. The presence of sarcomatoid carcinoma indicates poor prognosis, which also correlates with the amount of the sarcomatoid component. Therefore, the presence and quantity of sarcomatoid component should be reflected in pathology reports...
2017: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/28718911/clear-cell-renal-cell-carcinoma-validation-of-who-isup-grading
#18
Julien Dagher, Brett Delahunt, Nathalie Rioux-Leclercq, Lars Egevad, John R Srigley, Geoffrey Coughlin, Nigel Dunglinson, Troy Gianduzzo, Boon Kua, Greg Malone, Ben Martin, John Preston, Morgan Pokorny, Simon Wood, John Yaxley, Hemamali Samaratunga
AIM: In 2012, the International Society of Urological Pathology (ISUP) introduced a novel grading system for clear cell and papillary renal cell carcinoma (RCC) based upon increasing nucleolar prominence in grades 1 to 3, with the presence of extreme nuclear pleomorphism and/or tumour giant cells and/or sarcomatoid and/or rhabdoid differentiation as criteria for grade 4. This system is now incorporated in the latest World Health Organization renal tumour classification, being designated WHO/ISUP grading...
July 18, 2017: Histopathology
https://www.readbyqxmd.com/read/28716649/blood-platelet-volume-represents-a-novel-prognostic-factor-in-non-metastatic-renal-cell-carcinoma-patients-and-improves-the-predictive-ability-of-established-prognostic-scores
#19
Maximilian Seles, Florian Posch, Georg P Pichler, Thomas Gary, Karl Pummer, Richard Zigeuner, Georg C Hutterer, Martin Pichler
PURPOSE: The average size of blood platelets determined by the mean platelet volume (MPV), might represent a biologically meaningful parameter in carcinogenesis and potentially serve as novel prognostic biomarker in renal cell carcinoma (RCC). MATERIALS AND METHODS: In this retrospective analysis (n=652) we evaluated the potential prognostic value of MPV and its ability to improve existing risk assessment tools used in adjuvant clinical trials in non-metastatic RCC...
July 14, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28716439/renal-cell-carcinoma-unclassified-with-medullary-phenotype-poorly-differentiated-adenocarcinomas-overlapping-with-renal-medullary-carcinoma
#20
Deepika Sirohi, Steven C Smith, Chisato Ohe, Piergiuseppe Colombo, Mukul Divatia, Ema Dragoescu, Priya Rao, Michelle S Hirsch, Ying-Bei Chen, Rohit Mehra, Mahul B Amin
Renal medullary carcinoma (RMC) is a highly aggressive renal cell carcinoma, arising in the collecting system, and requiring careful correlation with status of sickle cell trait. A panel of international experts has recently proposed provisional diagnostic terminology, renal cell carcinoma, unclassified, with medullary phenotype (RCCU-MP), based on encountering an extraordinarily rare tumor with RMC morphology and immunophenotype in an individual proven not to have a hemoglobinopathy. Herein, we extend this observation to a cohort of five such tumors, morphologically similar to RMC, lacking SMARCB1 expression by immunohistochemistry, but each without evidence of a hemoglobinopathy...
July 14, 2017: Human Pathology
keyword
keyword
51054
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"